Washington, DC (November 14, 2024) — UsAgainstAlzheimer’s applauds the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for its positive opinion on the marketing authorization of Leqembi for the treatment of early Alzheimer’s disease. This decision marks a significant milestone for patients and families affected by Alzheimer’s disease in the European Union (EU).

Following an initial negative opinion, UsAgainstAlzheimer’s had joined leading European neurologists and Alzheimer Europe in calling for European regulators to give patients and their doctors an option to treat this deadly disease. Today, UsAgainstAlzheimer’s released the following statement in response to this updated opinion from EMA:

“The approval of Leqembi in the EU is huge for patients. It gives patients, their families, and their doctors an option to use the first drug that showed that it slowed down the relentless march of Alzheimer’s. It brings all of us one step closer to a future where people can live longer, more fulfilling lives, despite their diagnosis.

“We commend the European Medicines Agency for its dedication to advancing Alzheimer's research and treatment options, and we are optimistic about the potential impact of Leqembi on the lives of people with early-stage Alzheimer’s."

About UsAgainstAlzheimer’s
UsAgainstAlzheimer’s is engaged in a relentless pursuit to end Alzheimer’s, the sixth leading killer in America. Worldwide, more than 55 million people have dementia. Our work centers on prevention, early detection and diagnosis, and equal access to treatments regardless of gender, race, or ethnicity. To achieve our mission, we give voice to patients and caregivers while partnering with government, scientists, the private sector, and allied organizations -- the people who put the “Us” in UsAgainstAlzheimer’s.